Peptides for Anti-Aging and Longevity: What the Evidence Shows

No peptide has been shown in human trials to slow ageing or extend lifespan, and none is approved by the U.S. Food and Drug Administration (FDA) for that purpose as of 17 October 2026. The peptides marketed for “longevity” fall into three very different groups: compounds whose ageing claims rest mainly on cell and animal research, approved medicines whose approval covers a specific disease rather than ageing, and cosmetic ingredients aimed at the appearance of skin.

Ageing biology is usually described through a set of “hallmarks”, such as damage to DNA, shortening of telomeres (the protective ends of chromosomes), failing mitochondria (the energy-producing parts of cells), build-up of senescent (“zombie”) cells and long-running inflammation [1]. Most longevity peptides are promoted because they affect one of these hallmarks in a dish or in mice. That is a reasonable starting point for research, but it is not evidence that people who take the peptide live longer or stay healthier for longer (see Human vs Preclinical Research).

This guide sorts the peptides people search for most, epitalon, MOTS-c, elamipretide (SS-31), GHK-Cu, thymosin alpha-1 and growth hormone secretagogues, by the kind of evidence behind them. The wider research field is summarised on the Longevity Peptides research page. This guide describes research and regulatory status only. It gives no doses or instructions and is not medical advice.

The most direct test of an anti-ageing treatment would be a randomised trial showing that people who receive it live longer than people who receive a placebo. In humans, such a trial would need thousands of participants followed for decades. None has been done for any peptide, and none is likely soon.

Researchers therefore rely on surrogate endpoints: measurements that are easier and quicker to collect, such as telomere length, “epigenetic clock” scores, blood biomarkers, muscle strength or the activity of an enzyme. A surrogate is only useful if changing it reliably changes the outcome people care about, and for ageing that link has not been established for any of these measures. A peptide that lengthens telomeres in cultured cells, or lowers an epigenetic age score, has changed a number; it has not been shown to add healthy years.

Small human studies of “age reversal” show why caution is needed. In one widely reported study, a combination of growth hormone, DHEA and metformin was given to a small group of men to try to regenerate the thymus, and average epigenetic age scores fell over a year [2]. There was no randomised control group, several authors held commercial interests, and the study measured clocks and markers rather than illness or survival.

One proposed way forward is the TAME-style trial. The Targeting Aging with Metformin (TAME) concept, described in 2016, was to test whether a well-understood medicine delays a combination of age-related diseases, such as heart disease, cancer and dementia, plus death, rather than ageing itself, which regulators do not treat as a disease indication [3]. Even this design needs years and thousands of people. No peptide has been put through a trial of this kind. How trial design shapes what can be concluded is explained in How Clinical Trials Work and Understanding Evidence Levels.

What is epitalon? Epitalon (also spelled epithalon) is a synthetic peptide of four amino acids, Ala-Glu-Asp-Gly, designed on the basis of Epithalamin, an extract of cattle pineal gland [4]. Almost all of its research comes from the St Petersburg group led by Vladimir Khavinson and close collaborators.

• Cell studies: a 2003 report from the group found that adding epitalon to cultured human fetal fibroblasts switched on telomerase, the enzyme that rebuilds telomeres, and lengthened telomeres [5]. This is the source of most “telomere” claims online.
• Mouse studies: in a lifespan study in female mice, epitalon did not change average lifespan; it modestly increased the lifespan of the longest-lived animals and reduced leukaemia, while total tumour incidence was unchanged [6].
• Human data: the most cited human report followed 266 older people over 6 to 8 years and described lower death rates with Epithalamin and a thymus extract [7]. It tested the extract rather than the synthetic peptide, was not a modern placebo-controlled trial, and has not been independently repeated.

A 2025 review from an independent group in Poland summarised 25 years of epitalon research and noted that its mechanisms remain uncertain and that basic chemical and structural studies are limited [4]. In the United States, epitalon is not an approved medicine. The FDA lists it among bulk substances that may present significant safety risks in compounding, citing possible immune reactions and impurities and a lack of safety information [8]. For the compound-level summary, see the epitalon profile and the comparisons Semax vs Epitalon and Selank vs Epitalon.

MOTS-c is a short peptide encoded in mitochondrial DNA rather than in the cell nucleus. In the 2015 study that described it, giving MOTS-c to mice prevented diet-induced obesity and insulin resistance [9]. A 2021 study reported that MOTS-c improved physical performance in young, middle-aged and old mice, and that treatment started late in life improved physical capacity in old mice [10].

The human part of that 2021 paper was different: it measured the body’s own MOTS-c, which rose in muscle and blood after exercise. It did not give MOTS-c to people [10]. Two senior authors declared that they were consultants and shareholders of a company developing mitochondrial peptide drugs.

As of 17 October 2026, there are no published randomised trials of MOTS-c treatment in people. A phase 2 trial registered in 2026 is recruiting adults with prediabetes and overweight or obesity; its main outcome is insulin sensitivity, not ageing or lifespan, and no results are available [11]. MOTS-c is not an approved medicine, and it appears on the World Anti-Doping Agency prohibited list (see WADA peptide rules). More detail is on the MOTS-c profile and in MOTS-c vs BPC-157.

Elamipretide, long known in research as SS-31, is a four-amino-acid peptide that binds cardiolipin, a fat found in the inner membrane of mitochondria. On 19 September 2025 the FDA granted accelerated approval to Forzinity (elamipretide) as the first treatment for Barth syndrome, a rare inherited mitochondrial disease [12].

The basis for that approval was narrow. Accelerated approval relies on a measure judged “reasonably likely” to predict benefit; here it was improved strength of the knee-extending muscle, and the FDA requires a randomised, placebo-controlled confirmatory trial [12]. The supporting Barth syndrome trial, TAZPOWER, was very small: 10 patients entered its open-label extension and 8 reached the final visit; walking distance and other measures improved over time, without a placebo comparison in that phase [13].

Elsewhere, results have been disappointing. In MMPOWER-3, a phase 3 randomised trial of 218 adults with primary mitochondrial myopathy, elamipretide did not improve walking distance or fatigue compared with placebo [14]. Animal studies of ageing tissues are the main source of anti-ageing claims; no trial has tested elamipretide as an anti-ageing treatment in healthy people. “SS-31” sold online is not the FDA-approved product. See the elamipretide profile and What FDA Approval Means.

GHK-Cu is a three-amino-acid peptide bound to copper that occurs naturally in the body. Laboratory and gene-expression studies suggest effects on tissue repair, and reviews of this work, largely from the scientist who first described the peptide, propose wider anti-ageing roles [15]. Human evidence is limited to small studies of topical skin and wound products. Applying a peptide to skin is very different from injecting it, and the FDA lists injectable GHK-Cu among compounding substances that may present significant safety risks [8]. Skin products are covered in Topical Peptides and the Skin Barrier; see also the GHK-Cu profile.

Thymosin alpha-1 is a peptide first found in the thymus, the immune organ that shrinks with age. A synthetic version (thymalfasin) is approved in some countries outside the United States, but no FDA-approved product contains it. Its largest and best-controlled trial, TESTS, randomised 1,106 adults with sepsis and found no difference in 28-day death rates compared with placebo [16]. That trial does not address ageing at all, and claims that it “rejuvenates” the immune system are not backed by trials in healthy older people. The FDA also lists it among compounding substances that may present significant safety risks [8]. See the thymosin alpha-1 profile.

Growth hormone secretagogues, such as sermorelin, ipamorelin, CJC-1295 and tesamorelin, raise the body’s own growth hormone (see Growth Hormone Secretagogues). The anti-ageing idea is that restoring youthful growth hormone levels will restore youthful bodies. A systematic review of randomised trials of growth hormone itself in healthy older people found small changes in body composition, no change in weight or bone density, and more side effects, including swelling, joint pain, carpal tunnel syndrome and a tendency towards diabetes; the authors concluded that it could not be recommended as an anti-ageing therapy [17]. A two-year trial of MK-677 (ibutamoren), an oral non-peptide ghrelin mimetic, raised growth hormone and lean mass in healthy older adults, but strength and function did not improve and blood glucose rose [18]. The FDA cites a heart-failure safety signal for ibutamoren and identifies safety concerns for several peptide secretagogues in compounding [8]. Tesamorelin is approved, but only to reduce excess abdominal fat in people with HIV-associated lipodystrophy.

GLP-1 medicines such as semaglutide and tirzepatide are peptides, and they are often discussed in longevity circles. They are the clearest example of how age-related disease, rather than ageing, gets tested. In the SELECT trial, 17,604 adults with cardiovascular disease and overweight or obesity were randomised; semaglutide reduced the combined rate of cardiovascular death, heart attack or stroke compared with placebo [19]. That is a hard outcome in a defined group of patients, not proof of slower ageing in healthy people.

The limits are just as instructive. In the evoke and evoke+ phase 3 trials, oral semaglutide did not slow progression of early Alzheimer’s disease compared with placebo [20]. A medicine can reduce some age-related diseases without affecting others. The full scorecard is in GLP-1 Drugs Beyond Weight Loss, and the drug class is explained in How GLP-1 Drugs Work.

The table gives each compound’s U.S. status on 17 October 2026 and the strongest evidence found for an ageing-related claim. It summarises evidence; it is not a recommendation.

“RCT” means randomised controlled trial (see Randomized Controlled Trials).

Long-term safety is the biggest gap. An anti-ageing treatment would, by definition, be taken by healthy people for many years, yet the unapproved peptides in this guide have little or no controlled human safety data. Some proposed mechanisms carry their own theoretical concerns; for example, switching on telomerase or raising growth hormone and IGF-1 are pathways also linked to cell growth, and whether that matters for cancer risk in people is unknown.

Product quality is a separate problem. Peptides sold as “research use only” are not made or tested to medicine standards, and their identity, purity and sterility can differ from the label (see what “research use only” means, peptide impurities and approved versus unapproved peptides). Combining several peptides adds further unknowns, as discussed in Peptide Stacks. Whether any treatment is appropriate for a particular person is a decision for a licensed clinician.

Which peptides are best for anti-ageing?

Judged by evidence, none has been shown to slow ageing or extend life in people. Epitalon and MOTS-c rest mainly on cell and animal studies [6][10]. Elamipretide is approved only for Barth syndrome [12]. GLP-1 medicines have outcome trials for specific diseases, not for ageing itself [19].

Are peptides good for anti-ageing?

Some peptides act on processes linked to ageing in laboratory studies, and some approved peptide medicines reduce specific age-related diseases. That is different from showing that a peptide slows ageing in healthy people, which no trial has done.

What is epitalon peptide?

Epitalon is a synthetic four-amino-acid peptide based on a cattle pineal extract. Its telomere and lifespan claims come mostly from cell and mouse studies by one Russian research group, with few independent replications [5][4]. It is not an approved medicine.

What does MOTS-c do?

In mice, MOTS-c improved insulin sensitivity and physical performance [9][10]. In people, studies have only measured the body’s own MOTS-c, which rises with exercise. A first phase 2 treatment trial is recruiting [11].

Is SS-31 the same as elamipretide, and is it approved?

SS-31 is the research name for elamipretide. The FDA-approved product, Forzinity, has accelerated approval only for Barth syndrome, pending a confirmatory trial [12]. Products sold online as “SS-31” are not that product, and the approval says nothing about ageing.

What dose of anti-ageing peptides is used?

There is no established human dose for any peptide as an anti-ageing treatment, because no trial has shown that one works or is safe for that purpose. Questions about approved medicines belong with the prescriber and the product label.